Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05699642 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Online Tai Chi Plus Fitbit After ACS

Mind2Move
Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This projects studies the role of tai chi exercise and wearable fitness trackers to promote physical activity in acute coronary syndrome (ACS) survivors.

NCT ID: NCT05697640 Not yet recruiting - Post-COVID ME/CFS Clinical Trials

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

Start date: February 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the therapeutic value of an approved drug (Vericiguat) in patients with post-COVID-19 syndrome, who suffer from profound tiredness or fatigue, regardless of bed rest.The main questions it aims to answer are: • Does Vericiguat relieve fatigue and/or other symptoms associated with post-COVID-19 syndrome? • What are the side effects of Vericiguat in this patient population; and how common are they? Participants will be asked to participate for approx. 18 weeks. After screening, participants will receive assigned intervention of either 10 weeks of treatment with Vericiguat or matching placebo tablet, followed by 30 day follow-up period. Every participant will undergo trial, cardiovascular safety, and monitoring assessments. The results of this study will provide information on whether Vericiguat can alleviate PCS-related symptoms as well as insights into the pathophysiological processes of PCS, which in turn can help to develop therapies.

NCT ID: NCT05694130 Not yet recruiting - Clinical trials for Sjogren Syndrome With Other Organ Involvement

Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS

Start date: February 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.

NCT ID: NCT05688800 Not yet recruiting - Clinical trials for Myofascial Pain Syndrome

Pressure Release Versus Thoracic Manipulation in Rhomboids MPS

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of the stud will be to compare the effect of pressure release with thoracic spine manipulation on pain intensity level and pain pressure threshold, thoracic spine ROM and physical function onactive rhomboids muscle trigger point in myofascial pain syndrome.

NCT ID: NCT05687435 Not yet recruiting - Clinical trials for Diarrhea-Predominant Irritable Bowel Syndrome

Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Start date: January 30, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to test the efficacy and safety of the Chinese patent medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). The main questions it aims to answer are: 1. Can Changyanning Tablet improve diarrhea and abdominal pain in IBS-D patients? 2. Is Changchangning Tablet safe for the treatment of IBS-D?

NCT ID: NCT05684159 Not yet recruiting - Clinical trials for aHUS - Atypical Hemolytic Uremic Syndrome

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

Start date: October 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.

NCT ID: NCT05681663 Not yet recruiting - Clinical trials for Carpal Tunnel Syndrome

The Effectiveness of Extracorporeal Shock Wave Therapy for Management of Carpal Tunnel Syndrome

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Peripheral nerve entrapment neuropathies are the most common mononeuropathies in clinical practice. Carpal Tunnel Syndrome (CTS), n. It occurs as a result of compression of the medianus as it passes through the carpal tunnel, a narrow osteofibrous canal. CTS is the most common entrapment neuropathy of the upper extremity, affecting approximately 3% of the general adult population. This study, which was designed as a randomized controlled study, will include 36 patients with CTS, aged between 18-65, who applied to Kırşehir Ahi Evran University Training and Research Hospital. In our study, both groups will be given 10 minutes of paraffin, 20 minutes of TENS, and 10 repetitions of tendon gliding exercise, 3 days a week for a total of 3 weeks (9 sessions). EESDT will be applied once a week in both groups (one group at 4 bar and the other at 1.5 bar pressure). Measurements will be made before treatment, after treatment, and at 12 weeks post-treatment. In the literature, different pressure parameters were used in studies examining the efficacy of ESDT in the treatment of CTS. Although ESDT has been shown to have a curative effect on CTS, there is no consensus on which pressure parameter is more effective. Therefore, in this study, the effectiveness of ESDT applied at different pressure parameters in the treatment of CTS will be examined.

NCT ID: NCT05678335 Not yet recruiting - Clinical trials for Sjogren Syndrome With Other Organ Involvement

Tacrolimus for Thrombocytopenia in SS

Start date: February 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.

NCT ID: NCT05672472 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

Sepsis is a life-threatening organ dysfunction caused by the host's maladjusted response to infection. It is one of the common clinical critical diseases, often accompanied by multiple organ failure, immune imbalance and high mortality. Sepsis is a syndrome of physiological, pathological and biochemical abnormalities caused by infection. Its incidence rate and prevalence have been on the rise in the past few years. Sepsis has greatly endangered the lives and health of the public. Among them, ARDS is a fatal complication of sepsis and a common critical illness syndrome in ICU. At present, the conventional treatment for ARDS caused by sepsis is still limited to indirect supportive therapy such as primary disease treatment, infection control, mechanical ventilation support, and nutrition improvement, lacking specific direct treatment methods. So far, the drug treatment effect of ARDS at home and abroad is not satisfactory. Therefore, it has become an urgent task to find a new treatment strategy to alleviate ARDS. Neutrophil elastase inhibitors can reversibly and competitively inhibit the release of neutrophil elastase, inhibit the activation of neutrophils and the infiltration of inflammatory cells in the lungs, alleviate the release of inflammatory mediators, and thus improve respiratory function, which has a good protective effect on various experimental ARDS. However, the efficacy of neutrophil elastase inhibitor represented by sivelestat sodium in the treatment of ARDS has reached a relatively consistent positive conclusion in animal experiments, while the results of clinical studies are different. These differences in clinical research still need further analysis, research and verification in clinical trials. At present, the clinical studies of neutrophil elastase inhibitors in the treatment of sepsis induced ARDS are very few, and there is a lack of related prospective randomized controlled clinical studies. Therefore, further prospective clinical trials are needed to evaluate the therapeutic effect of neutrophil elastase inhibitors on sepsis induced ARDS patients. This study is intended to determine whether neutrophil elastase inhibitor can reduce the mechanical ventilation time, Murray lung injury score, ICU hospitalization time and 28-day mortality of septic ARDS patients compared with the control group through a single center randomized controlled trial, so as to provide a new basis for the treatment strategy of septic ARDS patients.

NCT ID: NCT05665296 Not yet recruiting - Clinical trials for Upper Crossed Syndrome

Effect of Cervicothoracic Mobilization on Upper Crossed Syndrome

Start date: April 2023
Phase: N/A
Study type: Interventional

PURPOSE: To investigate the effect of cervicothoracic mobilization on Craniovertebral angle (CVA), sagittal shoulder angle (SSA), kyphotic angle and pain intensity level in upper crossed syndrome.